Cedric is the CEO, co-founder, and a Board member of myNEO, a prominent biotech company specializing in advanced tumor characterization and target discovery for innovative immunotherapies focused on neoantigens. Leading the team, Cedric drives patient-centric therapy advancements through a digital tumor-profiling platform, enhancing cancer vaccine and cell therapy applications, patient stratification, and biomarker identification. With capital raised from Novalis biotech fund and key biopharma partnerships, myNEO is well-positioned for clinical development. Cedric's background includes oncology diagnostics and genomic advancements, with a Masters in Bioengineering and Medical Genetics from Ghent University and prior experience at Accenture Consulting's Life Sciences Industry Group.